Form 4 for URGN UroGen Pharma Ltd.
Accepted 2022-05-03 00:00:00 ET · period of report 2022-04-30 · accession 0001437749-22-010701 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-05-03 | 2022-04-30 | URGN | Schoenberg Mark | Chief Medical Off | S - Sale+OE | $6.62 | -254 | 23.5K | -1% | -$1,681 |
| D | 2022-05-03 | 2022-04-30 | URGN | Schoenberg Mark | Chief Medical Off | M - OptEx | — | +500 | 23.7K | +2% | — |
| D | 2022-05-03 | 2022-04-30 | URGN | Schoenberg Mark | Chief Medical Off | M - OptEx | $0.00 | -500 | 1,500 | -25% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2022-04-30 | S | D | 254 | $6.62 | 23,467 | D | — | — | (F2) Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units. |
| 2 | Common | Ordinary Shares | 2022-04-30 | M | A | 500 | — | 23,721 | D | — | — | (F1) Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer |
| 3 | Derivative | Restricted Stock Units | 2022-04-30 | M | D | 500 | $0.00 | 1,500 | D | — · — to — | 500 Ordinary Shares | (F1) Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer (F3) The reporting person was granted restricted stock units ("RSUs") on January 31, 2020 representing 6,000 ordinary shares. 33.33% of the RSUs vested on January 31, 2021 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter. |